Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial.
Amikacin
E. Coli
ESBL
Meropenem
UTIs
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
18
07
2023
accepted:
05
12
2023
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
25
1
2024
Statut:
epublish
Résumé
Urinary tract infections (UTIs) are very common infections in humans, and Escherichia coli (E. coli) is the commonest pathogen leading to UTIs. The generation of beta-lactamase enzymes in this bacterium results in its resistance against many antibiotics. This study compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs with E. coli in a double-blind clinical trial. The current double-blind clinical trial compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs with E. coli. The patients were assigned to two groups: Intervention (receiving a single dose of amikacin once a day at 48-h intervals for a week, three doses) and control (receiving meropenem for 1/TDS for a week). The E. coli infection frequency was 61 (21 cases of non-ESBL and 40 cases of ESBL-positive infections) and the frequency of the other infections was 52 (46%). In the patients with ESBL E. coli infection, ciprofloxacin (21; 70%) showed the highest antibiotic resistance, and nitrofurantoin (33; 91.7%) showed the highest sensitivity. The baseline variables between the control and intervention groups indicated no significant difference (p > 0.05). The frequency of signs and symptoms showed no significant difference between the amikacin and meropenem groups in the first 24 h and the first week. In the second week of follow-up, no clinical signs or symptoms were observed in the two groups. The results of this study showed that treatment with amikacin, 1 g q48h, for one week (three doses) has the same result as meropenem, 1 g q8h, for one week (21 doses). The results are the same for the treatment of UTIs with ESBL positive and ESBL negative. Amikacin can be used once every 48 h to treat UTIs, is less expensive and can be administered on an outpatient basis. This study was registered in the Iranian Registry of Clinical Trials (IRCT) with ID number: IRCT20170417033483N2 on the date 2018-02-13.
Identifiants
pubmed: 38273327
doi: 10.1186/s13104-023-06654-y
pii: 10.1186/s13104-023-06654-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Informations de copyright
© 2023. The Author(s).
Références
Cho S-Y, Choi S-M, Park SH, Lee D-G, Choi J-H, Yoo J-H. Amikacin therapy for urinary tract Infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Korean J Intern Med. 2016;31(1):156.
doi: 10.3904/kjim.2016.31.1.156
pubmed: 26767869
Nakazato G, Campos TAd, Stehling EG, Brocchi M, Silveira WD. Virulence factors of avian pathogenic Escherichia coli (APEC). Pesquisa Veterinária Brasileira. 2009;29(7):479–86.
doi: 10.1590/S0100-736X2009000700001
Kariyawasam S, Han J. Avian pathogenic Escherichia coli: link to foodborne urinary tract Infections in humans. Food Safety in Poultry Meat production. Springer; 2019. pp. 261–92.
de la Ortiz J-M, Nordmann P, Poirel L. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74(7):1934–9.
doi: 10.1093/jac/dkz149
Gona F, Mezzatesta M, Corona D, Zerbo D, Scriffignano V, Stefani S, et al. Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit. Infection. 2011;39(1):83–5.
doi: 10.1007/s15010-011-0081-0
pubmed: 21264678
Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N. Extended spectrum β-Lactamases among Gram-negative bacteria of nosocomial origin from an Intensive Care Unit of a tertiary health facility in Tanzania. BMC Infect Dis. 2005;5(1):86.
doi: 10.1186/1471-2334-5-86
pubmed: 16225701
pmcid: 1274314
McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, et al. Incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella Infections in the United States: a systematic literature review. Infect Control Hosp Epidemiol. 2017;38(10):1209–15.
doi: 10.1017/ice.2017.156
pubmed: 28758612
Bush KR, Ellison J, Hearn K, Pfister T, Taylor G. A comparison of extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli and Klebsiella pneumoniae bloodstream Infections in Alberta using a provincial surveillance system. Infect Control Hosp Epidemiol. 2019;40(3):388.
doi: 10.1017/ice.2018.353
pubmed: 30773162
van Hout D, Verschuuren TD, Bruijning-Verhagen PC, Bosch T, Schürch AC, Willems RJ, et al. Extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli isolates causing bacteremia in the Netherlands (2014–2016) differ in clonal distribution, antimicrobial resistance gene and virulence gene content. PLoS ONE. 2020;15(1):e0227604.
doi: 10.1371/journal.pone.0227604
pubmed: 31935253
pmcid: 6959556
Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates ofEscherichia Coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother. 2001;45(5):1402–6.
doi: 10.1128/AAC.45.5.1402-1406.2001
pubmed: 11302802
pmcid: 90480
Moniri R, Khorshidi A, Akbari H. Emergence of multidrug resistant strains of Escherichia coli isolated from urinary tract Infections. Iran J Public Health. 2003:42–6.
Stubbings W, Bostock J, Ingham E, Chopra I. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother. 2006;58(2):444–8.
doi: 10.1093/jac/dkl225
pubmed: 16735423
Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract Infection: is it time to resurrect an old strategy? Antimicrob Agents Chemother. 2019;63(1):e02165–18.
doi: 10.1128/AAC.02165-18
pubmed: 30397061
Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract Infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15(1):1–8.
doi: 10.1186/s12879-015-1153-z
Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial Drugs. Clin Chem. 1998;44(5):1129–40.
doi: 10.1093/clinchem/44.5.1129
pubmed: 9590397
Asakura T, Ikeda M, Nakamura A, Kodera S. Efficacy of empirical therapy with non-carbapenems for urinary tract Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2014;29:91–5.
doi: 10.1016/j.ijid.2014.08.018
pubmed: 25461239
Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract Infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15(1):414.
doi: 10.1186/s12879-015-1153-z
pubmed: 26464143
pmcid: 4604622
Poorabbas B, Mardaneh J, Rezaei Z, Kalani M, Pouladfar G, Alami MH, et al. Nosocomial Infections: Multicenter surveillance of antimicrobial resistance profile of Staphylococcus aureus and Gram negative rods isolated from blood and other sterile body fluids in Iran. Iran J Microbiol. 2015;7(3):127.
pubmed: 26668699
pmcid: 4676981
Soltani J, Poorabbas B, Miri N, Mardaneh J. Health care associated Infections, antibiotic resistance and clinical outcome: a surveillance study from Sanandaj. Iran World J Clin Cases. 2016;4(3):63.
doi: 10.12998/wjcc.v4.i3.63
pubmed: 26989670
Wie S-H, Kim H, Chang U-I. Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae in elderly and non-elderly women. Clin Microbiol Infect. 2014;20(11):1211–8.
doi: 10.1111/1469-0691.12711
pubmed: 24909648
Gage-Brown A, George C, Maleki J, Singh KP, Muhi S, editors. Is Piperacillin-Tazobactam an appropriate empirical Agent for Hospital-Acquired Sepsis and Community-Acquired septic shock of unknown origin in Australia? Healthcare. Multidisciplinary Digital Publishing Institute; 2022.
Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract Infection: a randomized clinical trial. JAMA. 2021;326(4):324–31.
doi: 10.1001/jama.2021.9899
pubmed: 34313686
pmcid: 8317010
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, et al. Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract Infections: a randomized clinical trial. JAMA Netw open. 2022;5(1):e2137277–e.
doi: 10.1001/jamanetworkopen.2021.37277
pubmed: 35024838
pmcid: 8759008